{"preliminary_commentary":{"by_channel":{"x_thread":59,"youtube":4,"podcast":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT01812369\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-01T08:32:38.921Z","note":"Automated from the 40 newest of 67 indexed sources (Jun 2023 – Sep 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":40,"text":"- Whether ddMVAC is the preferred neoadjuvant regimen\n- How treatment duration should be chosen\n- How ddMVAC tolerability and patient suitability should shape regimen choice\n- Whether the neoadjuvant survival signal is sufficient to guide treatment\n\nAlso discussed: molecular subtyping."},"drugs_tested":[["GC"]],"indication":"locally advanced bladder cancer","name":"VESPER","nct_id":"NCT01812369","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=vesper-nct01812369. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"VESPER","arms":[{"description":"gemcitabine 1250 mg/m2 D1 and D8 cisplatine 70 mg/m2 D1 each cycle every 3 weeks, 4 cycles","label":"GC","type":"EXPERIMENTAL"},{"description":"Methotrexate 30 mg/m2 D1 Vinblastine 3 mg/m2 D2 Doxorubicine 30 mg/m2 D2 Cisplatine 70 mg/m2 D2 G-CSF D3 and D9 Each cycle every 2 weeks, 6 cycles","label":"MVAC-HD","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-09-25","type":"ACTUAL"},"conditions":["Bladder Cancer"],"enrollment":{"count":500,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"GEMCITABINE CISPLATINE","otherNames":[],"type":"DRUG"},{"name":"METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF","otherNames":[],"type":"DRUG"}],"last_update":"2025-10-06","lead_sponsor":"University Hospital, Rouen","official_title":"Randomized Phase III Study of Gemcitabine/Cisplatine (GC) Versus High-dose Intensity Methotrexate, Vinblastine, Doxorubicine and Cisplatin (HD-MVAC) in the Perioperative Setting for Patients With Locally Advanced Transitional Cell Cancer of the Bladder","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-09-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) at 3 years","timeFrame":"3 years"}],"references":[{"citation":"Pfister C, Harter V, Fontugne J, Allory Y, Culine S; VESPER Trial Investigators. Prognostic Factors for Overall Survival in the VESPER Trial: Basal Molecular Subtype Is a Relevant Key Factor. Eur Urol Oncol. 2026 Jan 22:S2588-9311(26)00004-0. doi: 10.1016/j.euo.2026.01.003. Online ahead of print.","pmid":"41577609","type":"DERIVED"},{"citation":"Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study. Lancet Oncol. 2024 Feb;25(2):255-264. doi: 10.1016/S1470-2045(23)00587-9. Epub 2023 Dec 21.","pmid":"38142702","type":"DERIVED"},{"citation":"Pfister C, Gravis G, Flechon A, Chevreau C, Mahammedi H, Laguerre B, Guillot A, Joly F, Soulie M, Allory Y, Harter V, Culine S; VESPER Trial Investigators. Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial. J Clin Oncol. 2022 Jun 20;40(18):2013-2022. doi: 10.1200/JCO.21.02051. Epub 2022 Mar 7.","pmid":"35254888","type":"DERIVED"}],"start_date":{"date":"2013-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Perioperative Chemotherapy for Patients With Locally Advanced Bladder Cancer","url":"https://clinicaltrials.gov/study/NCT01812369"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/vesper-nct01812369"}